Legend Biotech Corp is a high-risk pharmaceutical company based in the United States of America. Specializing in novel cell therapies for oncology and other indications, the company's lead product candidate, LCAR-B38M/JNJ-4528, is a cutting-edge CAR T cell therapy for multiple myeloma. With a focus on ESG principles, Legend Biotech Corp generates revenue primarily through License and Collaboration revenue streams.